Tsg 101 rabbit pAb

SKU: ES7453

Size: 100μL

Source:Rabbit

Applications:WB;IHC;IF;ELISA

Reactivity:Human;Mouse;Rat;Monkey

Dilution:Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications.

Immunogen:The antiserum was produced against synthesized peptide derived from human TSG101. AA range:281-330

Storage_stability:-20°C/1 year

Clonality:Polyclonal

Isotype:IgG

Concentration:1 mg/ml

Observed_band(KD):44kD

Human_gene_id:7251

Human_swiss_prot_no:Q99816

Subcellular_location:Cytoplasm . Early endosome membrane ; Peripheral membrane protein ; Cytoplasmic side . Late endosome membrane ; Peripheral membrane protein. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Midbody, Midbody ring . Nucleus . Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Nuclear localization is cell cycle-dependent. Interaction with CEP55 is required for localization to the midbody during cytokinesis. .

Other_name:TSG101; Tumor susceptibility gene 101 protein; ESCRT-I complex subunit TSG101

Background:The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression. [provided by RefSeq, Jul 2008],